Search

Your search keyword '"Granito Alessandro"' showing total 584 results

Search Constraints

Start Over You searched for: Author "Granito Alessandro" Remove constraint Author: "Granito Alessandro"
584 results on '"Granito Alessandro"'

Search Results

1. Hypoalbuminemia and Risk of Portal Vein Thrombosis in Cirrhosis

2. Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib

4. Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma

5. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

7. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

8. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

9. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

10. Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

12. THU-472-YI Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab

13. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment

14. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

15. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience

16. Exploring Total Immunoglobulin A's Impact on Non-Biopsy Diagnosis of Celiac Disease: Implications for Diagnostic Accuracy.

17. Easy recognition and high autoimmune hepatitis specificity of smooth muscle antibodies giving an actin microfilament immunofluorescent pattern on embryonal vascular smooth muscle cells.

18. Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib.

19. Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib

20. Inter‐Reader Agreement for Contrast‐Enhanced Ultrasound Liver Imaging Reporting and Data System Major Features and Final Categorization

21. Immunophenotyping: a promising non-invasive approach to predict response to atezolizumab-bevacizumab in advanced hepatocellular carcinoma

22. Moderni aspetti di semeiotica medica. Interpretazione clinica di segni e sintomi ed elementi di diagnosi differenziale

23. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

28. Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy

29. From an understanding of etiopathogenesis to novel therapies--what is new in the treatment of celiac disease?

31. Genetic, Immunological, Dietary, Gut Microbiota, and Environmental Determinants of Osteoporosis in the Course of Celiac Disease: Which Factor Plays the First Violin in This Orchestra?

34. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules

36. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

39. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

41. Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma

43. Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

44. Autoimmune Polyendocrine Syndromes in Adult Italian Celiac Disease Patients.

45. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma

49. Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.

Catalog

Books, media, physical & digital resources